Arca
Skip to content
Tools
Tools

Edema

Drug research and approvals for edema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 191 studies of edema are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, FDA has 0 approved and 9 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 191
  • Trials authorized in Canada: 25
  • FDA orphan approvals: 0
  • EU medicines: 4

Recruiting Now

Newest start dates first, of 191 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

6 approved, 2 in phase 3, 3 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Spironolactone, Triamterene, Acetazolamide, Chlorothiazide, Hydrochlorothiazide, Witch hazel

Collagenase clostridium histolyticum
Phase 3 Collagen hydrolytic enzyme
Albumin human
Phase 3 Bilirubin sequestering agent
Tacrolimus anhydrous
Phase 2 FK506-binding protein 1A inhibitor
Fexofenadine
Phase 2 Histamine H1 receptor antagonist
Gelatin
Phase 2
Furosemide
Phase 1 Sodium-(potassium)-chloride cotransporter 2 inhibitor

How Its Trials Ended

827 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 227 whose ending is known, 48% met their primary endpoint, 5% missed it and 48% stopped early.

  • Completed, result not reported35543%
  • Status unknown12916%
  • Ongoing11614%
  • Met its primary endpoint10813%
  • Stopped: other or unclear668%
  • Stopped: enrollment or feasibility223%
  • Missed its primary endpoint111%
  • Stopped: lack of efficacy111%
  • Stopped: sponsor or business decision61%
  • Stopped: safety30%

Trials Authorized in Canada

The 10 newest of 25; search them all in Canada trials
Dec 21, 2022A phase III, multi¿center, randomized, double¿masked, sham¿controlled study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of…RO7200220 (IL-6 mab)RocheOngoing
Dec 12, 2022Cuff leak test and airway obstruction in mechanically ventilated icu patients (cosmic): a vanguard pilot randomized controlled trialDexamethasoneSt. Joseph'S Healthcare HamiltonClosed
Nov 22, 2022Treat & extend versus fixed dosing with faricimab for management of diabetic macular edema: a pragmatic, multi-center, open-label, randomized, controlled trialFaricimabMcmaster UniversityOngoing
Apr 1, 2022Evaluation of safety and efficacy of the ibe-814 intravitreal implant in patients with diabetic macular oedema and macular oedema due to retinal vein occlusion.IBE-814Ripple Therapeutics CorporationClosed
Mar 3, 2022A phase II, multicenter, randomized, double masked, active comparator controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and…RO7200220 / ranibizumab (RO4893594 )RocheOngoing
Mar 2, 2022A phase II, multicenter, randomized, double masked, active comparator controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and…RO7200220 (IL-6 mab) / ranibizumab (RO4893594 )RocheOngoing
Jun 30, 2021A phase 2a, prospective, multicenter, randomized, double-masked, sham-controlled study to assess the safety, tolerability and evidence of activity of a single…UBX1325Unity BiotechnologyClosed
Nov 6, 2020An exploratory, prospective, multi-center, open-label, single-arm, interventional, phase IIb study to investigate aqueous humor and multimodal imaging…Faricimab (RO6867461)RocheClosed
Nov 4, 2020Ozurdex in suboptimal diabetic macular edemaDexamethasoneDr Sohel SomaniPending
Apr 28, 2020A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edemaHigh-dose afliberceptRegeneronOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 25, 2026(S)-N-(4-(2-(4-chlorophenyl)but-3-yn-2-yl)…Treatment of retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndromeDrug FarmDesignated
Mar 4, 2025Tabirafusp alfaTreatment of uveitic macular edema (UME)Kodiak Sciences Inc.Designated
Aug 15, 2022VamikibartTreatment of uveitic macular edemaGenentech, IncDesignated
Jan 12, 2017GlyburideTreatment of severe cerebral edema in patients with acute ischemic strokeRemedy Pharmaceuticals, Inc.Designated
Jan 16, 2013Synthetic peptide;…Treatment of high altitude pulmonary edemaApeptico Forschung und Entwicklung GmbHDesignated
May 5, 2004IcatibantTreatment of burn patients hospitalized with burn-induced edemaShire Human Genetic TherapiesDesignated
Apr 6, 1998Corticotropin-releasing factor, humanTreatment of peritumoral brain edema.Neurobiological Technologies, Inc.Designated
Dec 22, 1993Neutrophil-endothelial interaction inhibitorTreatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.Cytel CorporationDesignated
Feb 22, 1990GlyceolTo decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.Chugai Pharmaceutical Co., Ltd.Designated

Medicines Authorised in the EU

Newest first
May 29, 2026BopediatFurosemideProveca Pharma LimitedEMA ↗
Sep 15, 2023YesafiliAflibercept · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
May 26, 2023QaialdoSpironolactoneLipomed GmbHEMA ↗
Jul 26, 2010OzurdexDexamethasoneAbbVie Deutschland GmbH & Co. KGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.